Our Faculty

David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M.

David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M.

Professor of Psychiatry

University of Maryland School of Medicine

Biography

Dr. David Gorelick is part-time professor of Psychiatry at the University of Maryland School of Medicine, having retired in October 2013 from the Intramural Research Program of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH) in Baltimore.

Dr. Gorelick received his M.D. and Ph.D. in Pharmacology from the Albert Einstein College of Medicine of Yeshiva University in 1976, and did his medical internship and psychiatric residency at the University of California Los Angeles (UCLA). After completing training in 1980 he joined the faculty of the UCLA Department of Psychiatry and the medical staff of the West Los Angeles Veterans Affairs Medical Center, where he directed inpatient and outpatient substance abuse treatment programs. He joined NIDA in 1989 as a tenured physician-scientist.

His research interests are the clinical pharmacology of substance abuse, substance withdrawal, and biological treatments of substance use disorders, including medication, drug-metabolizing enzymes, and transcranial magnetic stimulation, resulting in more than 200 peer-reviewed scientific articles.

Dr. Gorelick has authored or coauthored more than 50 book chapters and spoken at major national and international medical and scientific conferences. His recent work focuses on cannabis, including its potential therapeutic uses; cocaine; and individuals with comorbid psychiatric disorders.

He is board-certified in Psychiatry and Addiction Medicine, and is a distinguished Life Fellow of the American Psychiatric Association. He is also interested in the ethics of clinical research, serving for 10 years as chair of the NIDA Institutional Review Board and as a member of the NIH Human Subjects Research Advisory Committee and the NIH Committee on Scientific Conduct and Ethics.

Publications of David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M.

Quick Take Vol. 81

0.50 CMEs
Can ondansetron improve negative symptoms in schizophrenia? Will lithium orotate prevent or reverse Alzheimer's disease? What predicts treatment response in bipolar disorder? Should we increase SSRI doses or try alternative strategies for inadequate response? Is trazodone safe for treating insomnia in alcohol use disorder?
Faculty: Oliver Freudenreich, M.D., Scott R. Beach, M.D., Kristin Raj, M.D., Paul Zarkowski, M.D., David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M.
36.33 minutes in 5 audio sections

Quick Take Vol. 80

0.75 CMEs
How effective is the new antipsychotic KarXT using the number needed to treat metric? Can bright light therapy effectively treat bipolar depression without causing mania? Does IV haloperidol really increase cardiac risks as commonly believed? Can varenicline help reduce alcohol intake in people with alcohol use disorder? Does ashwagandha extract improve cognitive function in mild cognitive impairment?
Faculty: Oliver Freudenreich, M.D., Kristin Raj, M.D., Scott R. Beach, M.D., David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., Derick E. Vergne, M.D.
39.35 minutes in 5 audio sections

Quick Take Vol. 79

0.75 CMEs
How should clozapine monitoring change after FDA's REMS removal? Does cariprazine work equally well in older adults with bipolar disorder? Can semaglutide help treat alcohol use disorder? Why do older adults receive subtherapeutic antidepressant doses? Is saffron as effective as SSRIs for depression?
Faculty: Scott R. Beach, M.D., Oliver Freudenreich, M.D., David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., Kristin Raj, M.D., Derick E. Vergne, M.D.
44.22 minutes in 5 audio sections

Quick Take Vol. 78

0.50 CMEs
Can pramipexole help treatment-resistant bipolar depression? Does semaglutide work for clozapine-induced obesity? Which antipsychotics best prevent hospitalization after cannabis-induced psychosis? What treatments rank highest for treatment-resistant depression? How do gut microbiota differ in depression versus anxiety disorders?
Faculty: Kristin Raj, M.D., Oliver Freudenreich, M.D., Paul Zarkowski, M.D., Derick E. Vergne, M.D., David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M.
34.08 minutes in 5 audio sections

Quick Take Vol. 75

0.75 CMEs
What are the main considerations when choosing an antipsychotic for first-episode psychosis? How do side effects of antidepressants change over time? Do combinations of psychiatric medications increase Torsades risk? Is there sufficient evidence for psychedelics in treating substance use disorders? Can tea compounds benefit mood and sleep disorders through neurotransmitter modulation?
Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., Scott R. Beach, M.D., Paul Zarkowski, M.D., Oliver Freudenreich, M.D., Derick E. Vergne, M.D.
40.11 minutes in 5 audio sections

Quick Take Vol. 74

0.75 CMEs
What are the main reasons disulfiram is underutilized for alcohol use disorder? How do different antipsychotics compare regarding QT prolongation risks? What is the optimal dosage of lurasidone for bipolar depression ? How does clozapine's effectiveness compare to other antipsychotics? Which non-benzodiazepine medication options show the best balance of efficacy and side effects for insomnia in psychiatric patients?
Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., Scott R. Beach, M.D., Paul Zarkowski, M.D., Oliver Freudenreich, M.D., Kristin Raj, M.D.
41.07 minutes in 5 audio sections

Quick Take Vol. 73

0.75 CMEs
How do LAI antipsychotics impact mortality rates compared to oral medications in schizophrenia ? What dosages of medications are most effective for preventing bipolar disorder relapse and maintaining safety? Is olanzapine more effective than risperidone for managing BPS? Can lisdexamfetamine effectively treat methamphetamine use disorder? Does chronopharmacology impact psychiatric treatment efficacy and side effects?
Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., Scott R. Beach, M.D., Oliver Freudenreich, M.D., Kristin Raj, M.D., Derick E. Vergne, M.D.
43.14 minutes in 5 audio sections

Quick Take Vol. 72

0.50 CMEs
Can GLP-1 receptor agonists effectively treat alcohol use disorder? Which antidepressants cause the most weight gain? Do antidepressants increase fall risk in older adults? How effective and safe is ketamine for bipolar depression? Is aripiprazole truly a lower metabolic risk antipsychotic compared to olanzapine?
Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., Scott R. Beach, M.D., Paul Zarkowski, M.D., Oliver Freudenreich, M.D., Kristin Raj, M.D.
35.04 minutes in 5 audio sections

Quick Take Vol. 70

0.50 CMEs
How does clozapine affect OCD behaviors in schizophrenia patients? What is the relationship between valproate dosage and weight gain? Which dopamine agonist works best for treatment-resistant depression? Does delirium increase dementia risk in elderly patients? What treatment approaches show the strongest evidence for stimulant use disorder?
Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., Scott R. Beach, M.D., Paul Zarkowski, M.D., Oliver Freudenreich, M.D., Derick E. Vergne, M.D.
36.51 minutes in 5 audio sections

Quick Take Vol. 69

0.50 CMEs
How dangerous are clozapine-induced ileus and pneumonia compared to agranulocytosis? How does topiramate compare to naltrexone for alcohol use disorder? Should cariprazine be continued as maintenance therapy in bipolar disorder? How reliably can we diagnose Wernicke's encephalopathy? What role does gut bacteria play in major depression?
Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., Scott R. Beach, M.D., Oliver Freudenreich, M.D., Kristin Raj, M.D.
34.02 minutes in 5 audio sections

Quick Take Vol. 68

0.50 CMEs
What are the main benefits of long-acting injectables for women with schizophrenia? How might vitamin D impact dementia risk? What effect does lithium have on bone mineral density? How common is alcohol withdrawal syndrome? What are the long-term outcomes for patients with psychotic disorders?
Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., Scott R. Beach, M.D., Paul Zarkowski, M.D., Oliver Freudenreich, M.D.
31.4 minutes in 5 audio sections

Quick Take Vol. 67

0.50 CMEs
How common are antidepressant discontinuation symptoms and which medications are associated with higher rates? Can Akkermansia muciniphila help manage olanzapine-induced weight gain? How does climate change impact mental health outcomes? What is the current evidence for antidrug vaccines in treating substance use disorders? Are there cognitive deficits associated with COVID-19 infection and how significant are they?
Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., Scott R. Beach, M.D., Oliver Freudenreich, M.D.
33.39 minutes in 5 audio sections
1

Explore our library of over 440 video lectures, podcasts, research summaries and expert interviews.